IP Library Granted Patent US 10,668,105
Granted Patent B2
US 10,668,105 · App. 15/241,656 · Granted Jun 2, 2020

Methods of preparing and using novel stem cell compositions and kits comprising the same

Inventors: Robert J. Harman, Jr. (Ramona, CA); Theodore T. Sand (Poway, CA)
Assignee: VetStem Biopharma, Inc.
A61K35/35C12N5/0667A61K35/12C12N2509/00C12N2509/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,668,105
App. No.
15/241,656
Granted
Jun 2, 2020
Kind
B2
Abstract

The present invention provides novel stem cell compositions having significant therapeutic and practical advantages, as well as methods of preparing and using such compositions for the treatment and prevention of injury and disease in patients. The invention may be applied to stem cell populations isolated from a wide variety of animals, including humans, and tissues. In particular applications, the invention is used to prepare a stem cell composition from a collagen-based tissue, such as adipose tissue, isolated from a patient, and the stem cell composition is subsequently provided to a site of actual or potential injury in the patient. The invention further includes related kits comprising the stem cell compositions, which are remarkably stable and retain viability and efficacy during storage and shipment.

Claims (23)

1. A method of preparing a cell population comprising adipose-tissue derived stem cells useful for the treatment of an injury or disease, said method comprising:

(a) processing adipose tissue obtained from a mammal to release cells therein, wherein said processing releases cells and a fat layer; and

(b) separating cells released in (a) from the fat layer, thereby preparing the cell population comprising adipose tissue-derived stem cells;

wherein said method does not include isolating stem cells separated in (b) from other cells separated in (b), and

wherein the cell population obtained from (b) is useful for the treatment of an injury or disease and shows less than 20% reduction in viability following storage under refrigeration at 4° C. for 20-24 hours.

2. The method of claim 1 , wherein the processing of (a) comprises one or more procedures selected from the group consisting of: physical cutting or mincing of the adipose tissue; treating the adipose tissue with an enzyme that facilitates the release of cells; exposing the adipose tissue to ultrasonic energy; and treating the adipose tissue with perfluorocarbons.

3. The method of claim 1 , wherein the processing of (a) comprises physical cutting or mincing of the adipose tissue.

4. The method of claim 1 , wherein the separating of (b) comprises one or more procedures selected from the group consisting of: use of a density gradient; centrifugation; and filtration.

5. The method of claim 1 , wherein:

the processing of (a) comprises one or more procedures selected from the group consisting of: physical cutting or mincing of the adipose tissue; treating the adipose tissue with an enzyme that facilitates the release of cells; exposing the adipose tissue to ultrasonic energy; and treating the adipose tissue with perfluorocarbons; and

the separating of (b) comprises one or more procedures selected from the group consisting of: use of a density gradient; centrifugation; and filtration.

6. The method of claim 1 , wherein said cell population further comprises one or more cells selected from the group consisting of: red blood cells, white blood cells, fibroblasts, neutrophils, monocyte/macrophages, and basophils.

7. The method of claim 1 , wherein said cell population further comprises one or more other tissue components.

8. The method of claim 7 , wherein the one or more other tissue components comprise: extracellular matrix polypeptides, proteoglycans, lipids, cytokines, or growth factors.

9. The method of claim 1 , further comprising:

(c) freezing the cell population.

10. The method of claim 1 , further comprising:

(c) suspending the cell population in a physiologically compatible buffer.

11. The method of claim 1 , further comprising:

(c) placing the cell population in a container.

12. The method of claim 11 , wherein the container is a syringe.

13. The method of claim 11 , further comprising shipping the container comprising the cell population to a physician or veterinarian.

14. The method of claim 1 , further comprising storing the cell population under refrigeration.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2021
From: VETSTEM BIOPHARMA, INC.
To: VETSTEM, INC.
Reel/Frame 057882/0908 →
CHANGE OF NAME Recorded Sep 24, 2018
From: VET-STEM, INC.
To: VETSTEM BIOPHARMA, INC.
Reel/Frame 047130/0016 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2017
From: HARMAN, ROBERT J., JR; SAND, THEODORE T.
To: VET-STEM, INC.
Reel/Frame 041815/0345 →
Continuity (6)
Continuation 10575063
Provisional Application 60510021 · Oct 8, 2003
Provisional Application 60510022 · Oct 8, 2003
Provisional Application 60509928 · Oct 8, 2003
Provisional Application 60510072 · Oct 8, 2003
Related Publication 20170196912A1 · Jul 13, 2017
Cited By (1)
US 12,281,331